Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Dyne Therapeutics, Inc.”

49 pharma patents match "Dyne Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 49
Index total 30,257
Page 2 / 3

Quick answer

This filtered view shows 49 pharmaceutical patents matching "Dyne Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

49 results for “Dyne Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 11969475

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  2. US 11931421

    Muscle targeting complexes and formulations for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  3. US 11911484

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  4. US 11844843

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  5. US 11839660

    Anti-transferrin receptor antibody and uses thereof

    Dyne Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  6. US 11833217

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  7. US 11795233

    Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  8. US 11795234

    Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  9. US 11787869

    Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness

    Dyne Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  10. US 11771776

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  11. US 11759525

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  12. US 11679161

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  13. US 11672872

    Anti-transferrin receptor antibody and uses thereof

    Dyne Therapeutics, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  14. US 11648318

    Anti-transferrin receptor (TFR) antibody and uses thereof

    Dyne Therapeutics, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  15. US 11638761

    Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  16. US 11633498

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  17. US 11633496

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  18. US 11518816

    Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  19. US 11497815

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  20. US 11390682

    Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  21. US 11369689

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  22. US 11286305

    Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA

    Dyne Therapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  23. US 11248056

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  24. US 11168141

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted